Worth reading
28Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Who is moving to which position
Incoming appointee
1 itemScheduled Appointment Date1 October 2025
堀 英紀
Previous position取締役（あすか製薬株式会社 フェムテック事業推進室長 兼務）
New position代表取締役 社長（あすか製薬ホールディングス株式会社 執行役員、あすか製薬株式会社 フェムテック事業推進室長 兼務）
Departing officer
1 itemSaito Junichi (齋藤 淳一)Next role stated
Former Position代表取締役 社長（あすか製薬ホールディングス株式会社 執行役員）
New position取締役（あすか製薬ホールディングス株式会社 執行役員）
“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Whether the incumbent will remain in office (whether they will retain their position)
Continuing in office as Director
Directors after the change4Number
Executive officers are responsible for day-to-day business execution and hold positions separate from directors under the Companies Act.“Outside” refers to directors who oversee management without having come from the company.
| Item | Details |
|---|---|
| Scheduled Appointment Date | 1 October 2025 |
| Name of appointee | 堀 英紀 |
| Appointee's new position | 代表取締役 社長（あすか製薬ホールディングス株式会社 執行役員、あすか製薬株式会社 フェムテック事業推進室長 兼務） |
| Appointee's previous position | 取締役（あすか製薬株式会社 フェムテック事業推進室長 兼務） |
| Name of departing officer | Saito Junichi (齋藤 淳一) |
| Former position of departing officer | 代表取締役 社長（あすか製薬ホールディングス株式会社 執行役員） |
| New position of departing officer | 取締役（あすか製薬ホールディングス株式会社 執行役員） |
| Whether the incumbent will remain in office | Continuing in office as Director |
| Number of directors after the change | 4名（うち社外取締役はNot disclosed） |
Items this document does not state (12)
Resolution dateDate of departureAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeReason for departureReason for changeReasons for appointmentFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No specific reason for the changes is stated.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.